Abiomed Inc (ABMD)

136.73
0.85 0.63
NASDAQ : Health Care
Prev Close 135.88
Open 135.69
Day Low/High 135.69 / 137.39
52 Wk Low/High 67.81 / 119.90
Volume 172.70K
Avg Volume 292.00K
Exchange NASDAQ
Shares Outstanding 43.67M
Market Cap 5.89B
EPS 1.20
P/E Ratio 115.30
Div & Yield N.A. (N.A)

Latest News

Abiomed Marks Grand Opening Of Newly-Expanded Headquarters In Danvers, Massachusetts

Governor Baker joins heart recovery leader for grand opening of new manufacturing and training space that represents major investment in Massachusetts

Abiomed's Impella® Technology Showcased At 2017 American College Of Cardiology Scientific Session With More Than 10 Presentations

First Ever Scientific Presentation of Abiomed's Impella® Quality (IQ) Assurance Program

New Study Finds Abiomed Impella® Heart Pump Reduces Injury To Kidneys During High-Risk Percutaneous Coronary Intervention

Circulation Research paper supports previously published randomized clinical trial data

Masimo's Stock Is a Great Buy Right Now

Masimo's Stock Is a Great Buy Right Now

This patient-monitoring device-maker has plenty of room for growth.

Abiomed Surpasses 50,000 Impella® Patients Treated In The United States

Milestone Highlights Significant Unmet Need for Treatment Options Among Advanced Heart Failure Patients

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABMD, ABX, AEM, BGG, BIIB, HBM, HTBI, KALU, MNTA, NEWM, NQ, SNE, VMI, VPG, WMT, XCRA Downgrades: CGNX, DAKT, EXAC, FSLR, HOLI, PFLT Initiations: AGR Read on to get TheStreet Quant Ratings' detailed report:

Abiomed Celebrates 2017 American Heart Month

Leader in heart recovery technology highlights stories of women whose health and quality of life have been improved by Impella® heart pump

Abiomed Announces Q3 FY 2017 Revenue Of $114.7 Million, Up 34% Over Prior Year

Abiomed Announces Q3 FY 2017 Revenue Of $114.7 Million, Up 34% Over Prior Year

Largest Quarterly Sequential Revenue Increase in Company History

Abiomed Announces Preliminary Q3 FY 2017 Revenue Of $114.7 Million, Up 34% Over Prior Year

Abiomed Announces Preliminary Q3 FY 2017 Revenue Of $114.7 Million, Up 34% Over Prior Year

Largest Quarterly Sequential Revenue Increase in Company History

Abiomed Impella CP Receives Expanded FDA Approval For High-Risk Percutaneous Coronary Intervention (PCI) Procedures

Abiomed Impella CP Receives Expanded FDA Approval For High-Risk Percutaneous Coronary Intervention (PCI) Procedures

Impella 2.5, CP and 5.0 Only FDA Approved Percutaneous Heart Pumps Deemed Safe and Effective

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DLR, ESXB, IART, NMR, PBIB, PLNT, SANW, TCK Downgrades: AAN, ABMD, AXTA, CMC, CMPR, CVI, CVRR, DSPG, EHTH, ESSA, FCFS, NPTN, NWS, UHT, VDSI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Abiomed Receives FDA IDE Approval For Initiation Of Door To Unloading (DTU) Prospective Feasibility Study

Abiomed Receives FDA IDE Approval For Initiation Of Door To Unloading (DTU) Prospective Feasibility Study

Study Evaluates the Safety and Feasibility of Unloading of the Left Ventricle with Impella CP® in STEMI Patients, without Cardiogenic Shock

Abiomed's Impella Technology Showcased At TCT 2016 With More Than 25 Presentations During Scientific Sessions

Abiomed's Impella Technology Showcased At TCT 2016 With More Than 25 Presentations During Scientific Sessions

Abiomed is Committed to Improving Outcomes in Protected PCI and Cardiogenic Shock

Abiomed (ABMD) Hits New Lifetime High

Abiomed (ABMD) Hits New Lifetime High

Trade-Ideas LLC identified Abiomed (ABMD) as a new lifetime high candidate

Abiomed Announces Q1 FY 2017 Revenue Of $103.0 Million, Up 40% Over Prior Year

Abiomed Announces Q1 FY 2017 Revenue Of $103.0 Million, Up 40% Over Prior Year

Lower end of revenue guidance increased for FY 2017

'Mad Money' Lightning Round: Take Bristol-Myers Over Juno

'Mad Money' Lightning Round: Take Bristol-Myers Over Juno

Cramer says Abiomed is too expensive while Harman was hurt by the strong dollar.

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.

ABIOMED Stock Sees Short Interest Fall 12.5%

ABIOMED Stock Sees Short Interest Fall 12.5%

The most recent short interest data has been released for the 06/30/2016 settlement date, which shows a 365,960 share decrease in total short interest for ABIOMED, Inc. , to 2,561,708, a decrease of 12.50% since 06/15/2016.

Abiomed (ABMD) Hits New Lifetime High

Abiomed (ABMD) Hits New Lifetime High

Trade-Ideas LLC identified Abiomed (ABMD) as a new lifetime high candidate